College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China.
Int J Pharm. 2021 May 1;600:120477. doi: 10.1016/j.ijpharm.2021.120477. Epub 2021 Mar 16.
Mesenchymal stem cells (MSCs) have recently emerged as a promising living carrier for targeted drug delivery. A wealth of literature has shown evidence for great advances in MSCs-based drug delivery system (MSCs-DDS) in the treatment of various diseases. Nevertheless, as this field of study rapidly advances, several challenges associated with this delivery strategy have arisen, mainly due to the inherent limitations of MSCs. To this end, several novel technologies are being developed in parallel to improve the efficiency or safety of this system. In this review, we introduce recent advances and summarize the present challenges of MSCs-DDS. We also highlight some potential technologies to improve MSCs-DDS, including nanotechnology, genome engineering technology, and biomimetic technology. Finally, prospects for application of artificially improved MSCs-DDS are addressed. The technologies summarized in this review provide a general guideline for the improvement of MSCs-DDS.
间充质干细胞(MSCs)最近作为一种有前途的靶向药物传递的活体载体出现。大量文献表明,MSCs 为基于药物传递系统(MSCs-DDS)在治疗各种疾病方面的进展提供了有力证据。然而,随着该研究领域的快速发展,与该传递策略相关的一些挑战也随之出现,主要是由于 MSCs 的固有局限性。为此,正在开发一些新技术来提高该系统的效率或安全性。在这篇综述中,我们介绍了最近的进展,并总结了 MSCs-DDS 目前面临的挑战。我们还强调了一些提高 MSCs-DDS 的潜在技术,包括纳米技术、基因组工程技术和仿生技术。最后,探讨了人工改进的 MSCs-DDS 的应用前景。本综述中总结的技术为 MSCs-DDS 的改进提供了一般指导。
Adv Drug Deliv Rev. 2022-6
J Control Release. 2018-12-13
Endocr Metab Immune Disord Drug Targets. 2018
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018-5-25
Stem Cell Rev Rep. 2025-10
Cancer Cell Int. 2025-4-29
Int J Mol Sci. 2024-7-16
Pharmaceuticals (Basel). 2024-5-30